I think a starting point is this statement from the earlier...

I think a starting point is this statement from the earlier announcement from Cyp today -

"Dr RossMacdonald, Cynata’s Chief Executive Officer, said Thepurpose of this extension is to enable the parties to seek toaccommodate certain requests made by Fujifilm in relationto structural aspects of the GvHD license agreement."

Not to put to fine a point on it but Ross WTF are you talking about? That language is Orwellian.

It is hard to tell if this language is deliberately obtuse, just clumsy, or what? Will there be further clarifications of what this statement actually means perhaps in some CEO friendly follow up forum?

What seems clear - 1) Fujifilm made some requests. 2) Cynata could not immediately accommodate those requests - or they would have.

Those requests relate to "structural aspects of the GvHD licence agreement". But WTF is a structural aspect of a licence agreement? Isn't any term or clause of any written agreement a structural aspect and don't they just represent the paragraphs or sentences of the details of an overall deal?

In terms of some background context the MSC's actually seemed to work in the 15 patients so real sick people might actually benefit (ie not die or not die so badly and quickly) if some folks (whether they be at CYP at Fujifilm at the Japanese authority PDMA or elsewhere) can pull their proverbial fingers out and get a commercial deal done.

Delays in taking a life saving technology through to clinical application are life losing delays by definition.

People may be currently living whose cause of death may be incomplete or delayed "structural aspects of a GvHD licence agreement". Wouldn't they and their families be p*ssed if they knew.

Summary - the starting point is Ross, respectfully, WTF?